Literature DB >> 27162320

Distribution and clinical significance of circulating tumor cells in nasopharyngeal carcinoma.

Yongfeng Si1, Guiping Lan2, Zhuoxia Deng2, Yongli Wang2, Yan Lu3, Yangda Qin2, Bo Huang2, Yong Yang2, Jingjin Weng2, Xing Han2, Benjian Zhang2, Ying Qin2, Weimin Xiong2, Bing Li2, Shiyang Wu3.   

Abstract

OBJECTIVE: Nasopharyngeal carcinoma is one of the leading malignancies with obscure etiology. Circulating tumor cells have been showed to intimately correlate with characteristics in different kinds of cancer. But links between circulating tumor cells and nasopharyngeal carcinoma were still lacking. Therefore, we explored circulating tumor cells' distribution in nasopharyngeal carcinoma and their possible associations with nasopharyngeal carcinoma.
METHODS: Firstly, we found that the positive ratio of circulating tumor cells is extremely high in four stages of nasopharyngeal carcinoma. Meanwhile, positive ratios of mesenchymal circulating tumor cells were higher in early stages of nasopharyngeal carcinoma. Apart from epithelial circulating tumor cells, total, hybrid and mesenchymal circulating tumor cells were correlated with nasopharyngeal carcinoma clinical stage.
RESULTS: Our results showed that hybrid and mesenchymal circulating tumor cells were associated with nasopharyngeal carcinoma metastasis (both distant and lymph node) and smoking. Meanwhile, hybrid circulating tumor cells expressed the highest Epstein-Barr virus proteins and deoxyribonucleic acid in three types of circulating tumor cells. Moreover, we found that Epstein-Barr virus proteins viral-caspid antigen-immunoglobulin A (VCA/IgA) and early antigen-immunoglobulin A (EA/IgA), but not Epstein-Barr virus-deoxyribonucleic acid, had a closed association with nasopharyngeal carcinoma metastasis. However, Epstein-Barr virus hallmarks failed to associate with other nasopharyngeal carcinoma characteristics. Furthermore, we confirmed that matrix metalloproteinase 9 existed in circulating tumor cells and expressed most in mesenchymal circulating tumor cells. In addition, matrix metalloproteinase 9-expressed extent in hybrid circulating tumor cells is somewhat different from epithelial and mesenchymal circulating tumor cells in matrix metalloproteinase 9-positive circulating tumor cells. Nevertheless, matrix metalloproteinase 9 had no relationship with other nasopharyngeal carcinoma characteristics. Finally, our results showed that circulating tumor cells were decreased in patients after therapies.
CONCLUSION: Taken together, circulating tumor cells were tightly correlated with nasopharyngeal carcinoma characteristics. In addition, Epstein-Barr virus was associated with nasopharyngeal carcinoma metastasis. Of note, decreased circulating tumor cells indicated a favorable curative effect in nasopharyngeal carcinoma patients.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  CanPatrol™ CTC-enrichment technique; circulating tumor cells; matrix metalloproteinase 9; metastasis; nasopharyngeal carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27162320     DOI: 10.1093/jjco/hyw046

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  16 in total

Review 1.  Liquid Biopsy in Head and Neck Cancer: Current Evidence and Future Perspective on Squamous Cell, Salivary Gland, Paranasal Sinus and Nasopharyngeal Cancers.

Authors:  Santiago Cabezas-Camarero; Pedro Pérez-Segura
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

2.  Circulating Tumor Cells Undergoing the Epithelial-Mesenchymal Transition: Influence on Prognosis in Cytokeratin 19-Positive Hepatocellular Carcinoma.

Authors:  Qian Zhang; Wanting Xing; Jie Zhang; Junwen Hu; Lunan Qi; Bangde Xiang
Journal:  Onco Targets Ther       Date:  2021-03-02       Impact factor: 4.147

3.  The clinical value of detecting circulating tumour cells in the peripheral blood of nasopharyngeal carcinoma patients.

Authors:  Zhuo Chen; Lu Xu; Xinhua Xu; Chen Yuan
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

4.  Impact of liver tumor percutaneous radiofrequency ablation on circulating tumor cells.

Authors:  Yang Li; Na Huang; Chunlin Wang; Huanrong Ma; Minyu Zhou; Li Lin; Zhenhua Huang; Li Sun; Min Shi; Wangjun Liao
Journal:  Oncol Lett       Date:  2018-06-25       Impact factor: 2.967

5.  Circulating tumor cells: a valuable marker of poor prognosis for advanced nasopharyngeal carcinoma.

Authors:  Guoping Ou; Shan Xing; Jianpei Li; Lin Zhang; Shulin Chen
Journal:  Mol Med       Date:  2019-11-15       Impact factor: 6.354

6.  Correlation Between Postoperative Early Recurrence of Hepatocellular Carcinoma and Mesenchymal Circulating Tumor Cells in Peripheral Blood.

Authors:  Zhong Wang; Lei Luo; Yuan Cheng; Guolin He; Bangjian Peng; Yi Gao; Ze-Sheng Jiang; MingXin Pan
Journal:  J Gastrointest Surg       Date:  2017-11-20       Impact factor: 3.452

7.  Circulating tumor cells with karyotyping as a novel biomarker for diagnosis and treatment of nasopharyngeal carcinoma.

Authors:  Jing Zhang; Huashan Shi; Tingting Jiang; Zhe Liu; Peter P Lin; Nianyong Chen
Journal:  BMC Cancer       Date:  2018-11-19       Impact factor: 4.430

8.  Practical value of identifying circulating tumor cells to evaluate esophageal squamous cell carcinoma staging and treatment efficacy.

Authors:  Weipeng Chen; Yin Li; Dongfeng Yuan; Yinjie Peng; Jianjun Qin
Journal:  Thorac Cancer       Date:  2018-06-12       Impact factor: 3.500

9.  Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis.

Authors:  Changli Peng; Chunhui Zhou; Gang Li; Haiping Li; Liangrong Shi
Journal:  Clin Exp Metastasis       Date:  2019-12-20       Impact factor: 5.150

Review 10.  Epstein-Barr Virus-Encoded Products Promote Circulating Tumor Cell Generation: A Novel Mechanism of Nasopharyngeal Carcinoma Metastasis.

Authors:  Zongbei Yang; Jing Wang; Zhenlin Zhang; Faqing Tang
Journal:  Onco Targets Ther       Date:  2019-12-31       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.